JP2018506981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506981A5 JP2018506981A5 JP2017544615A JP2017544615A JP2018506981A5 JP 2018506981 A5 JP2018506981 A5 JP 2018506981A5 JP 2017544615 A JP2017544615 A JP 2017544615A JP 2017544615 A JP2017544615 A JP 2017544615A JP 2018506981 A5 JP2018506981 A5 JP 2018506981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- cdrs
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 210000004698 lymphocyte Anatomy 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 3
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 3
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000002463 transducing effect Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119793P | 2015-02-23 | 2015-02-23 | |
| US62/119,793 | 2015-02-23 | ||
| US201562241662P | 2015-10-14 | 2015-10-14 | |
| US62/241,662 | 2015-10-14 | ||
| US201662296560P | 2016-02-17 | 2016-02-17 | |
| US62/296,560 | 2016-02-17 | ||
| PCT/US2016/019192 WO2016138038A1 (en) | 2015-02-23 | 2016-02-23 | Anti-dll3 chimeric antigen receptors and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018506981A JP2018506981A (ja) | 2018-03-15 |
| JP2018506981A5 true JP2018506981A5 (OSRAM) | 2019-04-04 |
Family
ID=56789774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544615A Pending JP2018506981A (ja) | 2015-02-23 | 2016-02-23 | 抗ｄｌｌ３キメラ抗原受容体および使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20180044415A1 (OSRAM) |
| EP (1) | EP3261650A4 (OSRAM) |
| JP (1) | JP2018506981A (OSRAM) |
| KR (1) | KR20170120158A (OSRAM) |
| CN (1) | CN107405362A (OSRAM) |
| BR (1) | BR112017017927A2 (OSRAM) |
| CA (1) | CA2977502A1 (OSRAM) |
| CL (1) | CL2017002150A1 (OSRAM) |
| CO (1) | CO2017008804A2 (OSRAM) |
| CR (1) | CR20170436A (OSRAM) |
| DO (1) | DOP2017000199A (OSRAM) |
| EA (1) | EA201791884A1 (OSRAM) |
| EC (1) | ECSP17063327A (OSRAM) |
| HK (1) | HK1249405A1 (OSRAM) |
| IL (1) | IL254068A0 (OSRAM) |
| MA (1) | MA41613A (OSRAM) |
| MX (1) | MX2017010845A (OSRAM) |
| PE (1) | PE20171383A1 (OSRAM) |
| PH (1) | PH12017501521A1 (OSRAM) |
| SG (1) | SG11201706804SA (OSRAM) |
| TW (1) | TW201639887A (OSRAM) |
| WO (1) | WO2016138038A1 (OSRAM) |
| ZA (1) | ZA201705720B (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US20230027993A1 (en) | 2014-03-05 | 2023-01-26 | Autolus Limited | Methods |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| KR20190080992A (ko) | 2015-05-21 | 2019-07-08 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3235295C (en) | 2017-02-20 | 2024-11-19 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| AU2018304711B2 (en) | 2017-07-20 | 2025-04-10 | Cytomx Therapeutics, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
| KR102172092B1 (ko) | 2017-09-19 | 2020-10-30 | 주식회사 엘지화학 | 열가소성 수지 조성물, 이의 제조방법 및 성형품 |
| PL3694529T3 (pl) | 2017-10-13 | 2024-12-16 | Harpoon Therapeutics, Inc. | Trójswoiste białka i sposoby zastosowania |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US20190117153A1 (en) * | 2017-10-20 | 2019-04-25 | Nantbio, Inc. | Methods for monitoring bladder cancer immunotherapy |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| US11110125B2 (en) * | 2018-02-13 | 2021-09-07 | Chimera Bioengineering, Inc. | Coordinating gene expression using RNA destabilizing elements |
| US12215157B2 (en) | 2018-02-20 | 2025-02-04 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use |
| WO2019195408A1 (en) * | 2018-04-03 | 2019-10-10 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| TWI842703B (zh) * | 2018-04-10 | 2024-05-21 | 美商安進公司 | Dll3 的嵌合受體及其使用方法 |
| KR20210006913A (ko) | 2018-04-11 | 2021-01-19 | 인히브릭스, 인크. | 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| US12037391B2 (en) * | 2018-05-08 | 2024-07-16 | Phanes Therapeutics, Inc. | Anti-DLL3 antibodies and uses thereof |
| MX2020012217A (es) | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| TW202035451A (zh) | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| US20230158071A1 (en) * | 2018-12-07 | 2023-05-25 | Crage Medical Co., Limited | Tumor combined immunotherapy |
| BR112021016984A2 (pt) * | 2019-03-01 | 2021-11-30 | Allogene Therapeutics Inc | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação |
| CN113874526A (zh) * | 2019-03-08 | 2021-12-31 | 肿瘤实验室诊断有限公司 | 癌症的诊断和预后 |
| BR112021016272A2 (pt) * | 2019-04-08 | 2021-11-09 | Phanes Therapeutics Inc | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos |
| CN117106099A (zh) * | 2019-07-17 | 2023-11-24 | 南京传奇生物科技有限公司 | 一种抗dll3嵌合抗原受体及其用途 |
| US20210046117A1 (en) * | 2019-08-18 | 2021-02-18 | Chimera Bioengineering, Inc. | Combination Therapy with Gold Controlled Transgenes |
| US12486331B2 (en) | 2020-01-31 | 2025-12-02 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| JP2023512297A (ja) * | 2020-01-31 | 2023-03-24 | ゲンサン バイオファーマ インコーポレイテッド | 二重特異性ｔ細胞エンゲージャー |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN113444171A (zh) * | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US20240150456A1 (en) * | 2021-04-02 | 2024-05-09 | Nanjing Legend Biotech Co., Ltd. | Engineered immune cells and uses thereof |
| CA3230627A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
| CN120641113A (zh) | 2023-03-31 | 2025-09-12 | 西比曼生物科技集团 | 靶向cd20和bcma的双特异性嵌合抗原受体 |
| CN117169518B (zh) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒 |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2530091T3 (en) * | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| ES2812849T3 (es) * | 2012-02-24 | 2021-03-18 | Abbvie Stemcentrx Llc | Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos |
| EP2863948B1 (en) * | 2012-06-22 | 2018-10-24 | Cytomx Therapeutics Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| ES2731681T3 (es) * | 2013-02-22 | 2019-11-18 | Abbvie Stemcentrx Llc | Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos |
| WO2016179319A1 (en) * | 2015-05-04 | 2016-11-10 | Cellerant Therapeutics, Inc. | Chimeric antigen receptors with ctla4 signal transduction domains |
-
2016
- 2016-02-22 MA MA041613A patent/MA41613A/fr unknown
- 2016-02-23 HK HK18108019.0A patent/HK1249405A1/zh unknown
- 2016-02-23 PE PE2017001455A patent/PE20171383A1/es unknown
- 2016-02-23 EA EA201791884A patent/EA201791884A1/ru unknown
- 2016-02-23 KR KR1020177026963A patent/KR20170120158A/ko not_active Withdrawn
- 2016-02-23 US US15/553,102 patent/US20180044415A1/en not_active Abandoned
- 2016-02-23 JP JP2017544615A patent/JP2018506981A/ja active Pending
- 2016-02-23 MX MX2017010845A patent/MX2017010845A/es unknown
- 2016-02-23 TW TW105105289A patent/TW201639887A/zh unknown
- 2016-02-23 CN CN201680019227.8A patent/CN107405362A/zh active Pending
- 2016-02-23 SG SG11201706804SA patent/SG11201706804SA/en unknown
- 2016-02-23 CR CR20170436A patent/CR20170436A/es unknown
- 2016-02-23 CA CA2977502A patent/CA2977502A1/en not_active Abandoned
- 2016-02-23 BR BR112017017927A patent/BR112017017927A2/pt not_active IP Right Cessation
- 2016-02-23 WO PCT/US2016/019192 patent/WO2016138038A1/en not_active Ceased
- 2016-02-23 EP EP16756219.8A patent/EP3261650A4/en not_active Withdrawn
-
2017
- 2017-08-20 IL IL254068A patent/IL254068A0/en unknown
- 2017-08-22 ZA ZA2017/05720A patent/ZA201705720B/en unknown
- 2017-08-23 CL CL2017002150A patent/CL2017002150A1/es unknown
- 2017-08-23 DO DO2017000199A patent/DOP2017000199A/es unknown
- 2017-08-23 PH PH12017501521A patent/PH12017501521A1/en unknown
- 2017-08-29 CO CONC2017/0008804A patent/CO2017008804A2/es unknown
- 2017-09-22 EC ECIEPI201763327A patent/ECSP17063327A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506981A5 (OSRAM) | ||
| Oren et al. | Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody–based chimeric antigen receptors indicates affinity/avidity thresholds | |
| JP7233425B2 (ja) | 細胞療法とガンマセクレターゼ阻害剤との組み合わせ | |
| Kleber et al. | BCMA in multiple myeloma—a promising key to therapy | |
| JP7299841B2 (ja) | 細胞療法と免疫調節化合物の併用 | |
| KR102853341B1 (ko) | 조작된 ｔ 세포의 조성물을 제조하는 방법 | |
| Bluhm et al. | CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin’s lymphoma and multiple myeloma | |
| RU2018111462A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| FI3946621T3 (fi) | Mage a4 -t-solureptoreja | |
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2016534717A5 (OSRAM) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| RU2017100003A (ru) | Улучшенные композиции на основе t-клеток | |
| EP3664820B1 (en) | Methods for producing genetically engineered cell compositions and related compositions | |
| JP2020515259A5 (OSRAM) | ||
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| FI3708579T3 (fi) | Claudin-6-spesifiset immuunoreseptorit ja t-soluepitoopit | |
| JP2017527275A5 (OSRAM) | ||
| JP2015513920A5 (OSRAM) | ||
| JP2018529327A5 (OSRAM) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2015508757A5 (OSRAM) | ||
| JP2019513347A5 (OSRAM) |